HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Spinowitz, B. S. Search for Related Content PubMed PubMed Citation Articles by Spinowitz, B. S.

Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin

New York Hospital, Queens, Cornell University Medical Center, New York, NY, USA

Correspondence: Bruce S. Spinowitz, M.D. FACP, Associate Director, Nephrology, Associate Chairman, Medicine, New York Hospital, Queens, Clinical Professor of Medicine, Cornell University Medical Center, New York, NY, USA. E-mail: bss9001{at}nyp.org

In a one-year, multicenter, open-label, uncontrolled trial, epoetin was given subcutaneously, 1–3-times weekly to peritoneal dialysis patients who had previously received an epoetin. Dose was adjusted to maintain hemoglobin at 10.0–12.0 g/dL. The primary endpoint was mean hemoglobin over weeks 12–24. Safety was assessed. Mean±SD baseline hemoglobin was 11.2±0.9 g/dL. Hemoglobin over weeks 12–24 was 11.6±1.1 g/dL. Adverse events were those expected in this patient population. No life-threatening adverse events occurred. Subcutaneous epoetin was effective and well tolerated for the treatment of anemia in peritoneal dialysis patients.

Key words: anemia, peritoneal dialysis, epoetin.